Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center

Lukasz Kwapisz, Laura E. Raffals, David H. Bruining, Darrell S. Pardi, William J. Tremaine, Sunanda V. Kane, Konstantinos A. Papadakis, Nayantara Coelho-Prabhu, John B. Kisiel, Valerie Heron, William A. Faubion, Edward V. Loftus

Research output: Contribution to journalShort surveypeer-review

3 Scopus citations

Abstract

The global incidence of inflammatory bowel disease (IBD) has increased considerably during the past few decades.1 IBDs, composed of Crohn's disease (CD) and ulcerative colitis (UC), are characterized by heterogeneous presentation and widely variable clinical course. The therapeutic goals are to induce and maintain remission. Despite the current treatments available, many patients do not achieve this goal.

Original languageEnglish (US)
Pages (from-to)616-617
Number of pages2
JournalClinical Gastroenterology and Hepatology
Volume19
Issue number3
DOIs
StatePublished - Mar 2021

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center'. Together they form a unique fingerprint.

Cite this